Holen Sie sich die Stockscreener-App
116.20
2.65%
3.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$113.20
Offen:
$114.555
24-Stunden-Volumen:
7.78M
Relative Volume:
0.98
Marktkapitalisierung:
$144.54B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
24.46
EPS:
4.75
Netto-Cashflow:
$9.84B
1W Leistung:
+7.37%
1M Leistung:
+9.70%
6M Leistung:
+24.85%
1J Leistung:
+51.88%
1-Tages-Spanne:
$114.13
$117.60
1-Wochen-Bereich:
$107.75
$117.60
52-Wochen-Spanne:
$72.43
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
116.20 | 140.81B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Why Gilead Sciences Stock Just Popped - Yahoo Finance
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus
Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits
Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha
Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace
Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria
Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest
What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace
Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks
Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks
Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)
AG Jackson announces major settlement with Gilead Sciences over kickbacks - WLOS
Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView
Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter
Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire
What analysts say about Gilead Sciences Inc. stockHigh-octane investment gains - Autocar Professional
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks
Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda - insights.citeline.com
After Gilead Deal, Hookipa Hangs Up Its Hat - insights.citeline.com
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - MSN
Hookipa, having sold off vaccines to Gilead, opts to wind down - Fierce Biotech
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Gilead Sciences Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com
Gilead’s HIV Strength Drives Gains, But Pipeline Is Key - Finimize
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector - MSN
Is Gilead Sciences Inc. a good long term investmentFree Wealth Planning Blueprint - Jammu Links News
Lobbying Update: $90,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
Gilead Sciences Trading Volume Surges 54.53% to $720 Million Ranking 154th in Market Activity - AInvest
HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences - Quiver Quantitative
HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan
Foster City drugs giant Gilead to pay $202 million over alleged kickback scheme - SiliconValley.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.21%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):